Iovance reaffirms FY2025 revenue guidance of $250-300M; cash $307M as of Q3

IOVANCE BIOTHERAPEUTICS, INC.

Expects to achieve previously disclosed FY2025 revenue guidance of $250-300M in first full year of Amtagvi sales.
Cash position of $307M as of 9/30/25, expected to fund operations into Q2 2027.
85 authorized treatment centers as of 12/31/25; over 1,000 patients treated with commercial and clinical TIL products.
Gross margin of 43% in Q3 2025; organization streamlined in Q3 2025 to support improved margins.
IOV-LUN-202 NSCLC trial enrollment complete; data update expected in 2026 with potential launch in H2 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.